These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 19852734)

  • 1. Nonsteroidal selective androgen receptor modulator Ostarine in cancer cachexia.
    Zilbermint MF; Dobs AS
    Future Oncol; 2009 Oct; 5(8):1211-20. PubMed ID: 19852734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enobosarm (GTx-024, S-22): a potential treatment for cachexia.
    Srinath R; Dobs A
    Future Oncol; 2014 Feb; 10(2):187-94. PubMed ID: 24490605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).
    Crawford J; Prado CM; Johnston MA; Gralla RJ; Taylor RP; Hancock ML; Dalton JT
    Curr Oncol Rep; 2016 Jun; 18(6):37. PubMed ID: 27138015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer.
    Dalton JT; Taylor RP; Mohler ML; Steiner MS
    Curr Opin Support Palliat Care; 2013 Dec; 7(4):345-51. PubMed ID: 24189892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications.
    Solomon ZJ; Mirabal JR; Mazur DJ; Kohn TP; Lipshultz LI; Pastuszak AW
    Sex Med Rev; 2019 Jan; 7(1):84-94. PubMed ID: 30503797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer cachexia: it's time for more clinical trials.
    Bossola M; Pacelli F; Tortorelli A; Doglietto GB
    Ann Surg Oncol; 2007 Feb; 14(2):276-85. PubMed ID: 17094025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emerging role of anamorelin hydrochloride in the management of patients with cancer anorexia-cachexia.
    Currow DC; Skipworth RJ
    Future Oncol; 2017 Aug; 13(20):1767-1783. PubMed ID: 28621564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials.
    Garcia JM; Boccia RV; Graham CD; Yan Y; Duus EM; Allen S; Friend J
    Lancet Oncol; 2015 Jan; 16(1):108-16. PubMed ID: 25524795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on promising agents for the treatment of cancer cachexia.
    Madeddu C; Mantovani G
    Curr Opin Support Palliat Care; 2009 Dec; 3(4):258-62. PubMed ID: 19667995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist.
    Esposito A; Criscitiello C; Gelao L; Pravettoni G; Locatelli M; Minchella I; Di Leo M; Liuzzi R; Milani A; Massaro M; Curigliano G
    Cancer Treat Rev; 2015 Nov; 41(9):793-7. PubMed ID: 26386985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multitargeted treatment of cancer cachexia.
    Madeddu C; Maccio A; Mantovani G
    Crit Rev Oncog; 2012; 17(3):305-14. PubMed ID: 22831161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigational drugs for the treatment of cancer cachexia: a focus on phase I and phase II clinical trials.
    Molfino A; Amabile MI; Giorgi A; Monti M; D'Andrea V; Muscaritoli M
    Expert Opin Investig Drugs; 2019 Aug; 28(8):733-740. PubMed ID: 31347405
    [No Abstract]   [Full Text] [Related]  

  • 13. [Recent development in research and management of cancer anorexia-cachexia syndrome].
    Inui A
    Gan To Kagaku Ryoho; 2005 Jun; 32(6):743-9. PubMed ID: 15984510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cachexia in cancer: is it treatable at the molecular level?
    Vanchieri C
    J Natl Cancer Inst; 2010 Nov; 102(22):1694-7. PubMed ID: 21060062
    [No Abstract]   [Full Text] [Related]  

  • 15. [Feeding-related disorders in medicine, with special reference to cancer anorexia-cachexia syndrome].
    Inui A
    Rinsho Byori; 2006 Oct; 54(10):1044-51. PubMed ID: 17133993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer-related cachexia and oxidative stress: beyond current therapeutic options.
    Mantovani G; Macciò A; Madeddu C; Massa E
    Expert Rev Anticancer Ther; 2003 Jun; 3(3):381-92. PubMed ID: 12820780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of body weight loss and sarcopenia by a novel selective androgen receptor modulator in cancer cachexia models.
    Morimoto M; Aikawa K; Hara T; Yamaoka M
    Oncol Lett; 2017 Dec; 14(6):8066-8071. PubMed ID: 29344250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial update on emerging drugs for cancer cachexia.
    Murphy KT; Lynch GS
    Expert Opin Emerg Drugs; 2012 Mar; 17(1):5-9. PubMed ID: 22229463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials.
    Advani SM; Advani PG; VonVille HM; Jafri SH
    BMC Cancer; 2018 Nov; 18(1):1174. PubMed ID: 30482179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in pharmacologic strategies for cancer cachexia.
    Madeddu C; Mantovani G; Gramignano G; Macciò A
    Expert Opin Pharmacother; 2015; 16(14):2163-77. PubMed ID: 26330024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.